Sept 21 (Reuters) - Shares of VeriChip Corp tripled
after it said it had been granted an exclusive license to two
patents held by its development partner Receptors LLC to detect
the H1N1 virus.
The patents can also be applied to detection systems for other viruses and biological threats such as methicillin-resistant staphylococcus aureus, VeriChip said in a statement.
VeriChip develops, markets and sells radio frequency identification (RFID) systems used for the identification and protection of people in the healthcare market.
Shares of VeriChip were up 185 percent at $3.26 Monday morning on Nasdaq. They had touched a year high of $3.43 earlier in the session.
(Reporting by Mansi Dutta in Bangalore; Editing by Mike Miller) Keywords: VERICHIP/SHARES (mansi.dutta@thomsonreuters.com; within U.S. +1 646 223 8780;outside U.S. +91 80 4135 5800; Reuters Messaging: mansi.dutta.thomsonreuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
The patents can also be applied to detection systems for other viruses and biological threats such as methicillin-resistant staphylococcus aureus, VeriChip said in a statement.
VeriChip develops, markets and sells radio frequency identification (RFID) systems used for the identification and protection of people in the healthcare market.
Shares of VeriChip were up 185 percent at $3.26 Monday morning on Nasdaq. They had touched a year high of $3.43 earlier in the session.
(Reporting by Mansi Dutta in Bangalore; Editing by Mike Miller) Keywords: VERICHIP/SHARES (mansi.dutta@thomsonreuters.com; within U.S. +1 646 223 8780;outside U.S. +91 80 4135 5800; Reuters Messaging: mansi.dutta.thomsonreuters.com@reuters.net) COPYRIGHT Copyright Thomson Reuters 2009. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.